162 related articles for article (PubMed ID: 16815701)
1. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review.
Neal CP; Garcea G; Doucas H; Manson MM; Sutton CD; Dennison AR; Berry DP
Eur J Cancer; 2006 Aug; 42(12):1728-43. PubMed ID: 16815701
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases.
Galjart B; Nierop PMH; van der Stok EP; van den Braak RRJC; Höppener DJ; Daelemans S; Dirix LY; Verhoef C; Vermeulen PB; Grünhagen DJ
Angiogenesis; 2019 May; 22(2):355-368. PubMed ID: 30637550
[TBL] [Abstract][Full Text] [Related]
3. p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer.
Saw RP; Koorey D; Painter D; Gallagher PJ; Solomon MJ
Br J Surg; 2002 Nov; 89(11):1409-15. PubMed ID: 12390383
[TBL] [Abstract][Full Text] [Related]
4. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?
Graziano F; Cascinu S
Ann Oncol; 2003 Jul; 14(7):1026-38. PubMed ID: 12853343
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in colorectal liver metastases.
Yamashita S; Chun YS; Kopetz SE; Vauthey JN
Br J Surg; 2018 May; 105(6):618-627. PubMed ID: 29579319
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive factors in colorectal cancer.
Bolocan A; Ion D; Ciocan DN; Paduraru DN
Chirurgia (Bucur); 2012; 107(5):555-63. PubMed ID: 23116828
[TBL] [Abstract][Full Text] [Related]
8. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.
Qin LX; Tang ZY
J Cancer Res Clin Oncol; 2004 Sep; 130(9):497-513. PubMed ID: 15205947
[TBL] [Abstract][Full Text] [Related]
10. Predicting early intrahepatic recurrence after curative resection of colorectal liver metastases with molecular markers.
Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Yamamoto T; Addeo P; Jaeck D; Bachellier P
World J Surg; 2015 May; 39(5):1167-76. PubMed ID: 25561185
[TBL] [Abstract][Full Text] [Related]
11. SMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases.
López-Gómez M; Moreno-Rubio J; Suárez-García I; Cejas P; Madero R; Casado E; Jiménez A; Sereno M; Gómez-Raposo C; Zambrana F; Merino M; Fernández-Luengas D; Feliu J
Clin Transl Oncol; 2015 Feb; 17(2):133-8. PubMed ID: 25060566
[TBL] [Abstract][Full Text] [Related]
12. Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis.
Søreide K; Watson MM; Lea D; Nordgård O; Søreide JA; Hagland HR;
J Transl Med; 2016 Jun; 14(1):192. PubMed ID: 27357108
[TBL] [Abstract][Full Text] [Related]
13. Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer.
Onodera H; Mori A; Nagayama S; Fujimoto A; Tachibana T; Yonenaga Y; Tsuruyama T
Int J Colorectal Dis; 2005 Nov; 20(6):477-84. PubMed ID: 15846499
[TBL] [Abstract][Full Text] [Related]
14. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
Saw RP; Morgan M; Koorey D; Painter D; Findlay M; Stevens G; Clarke S; Chapuis P; Solomon MJ
Dis Colon Rectum; 2003 Feb; 46(2):192-202. PubMed ID: 12576893
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go?
Ihnát P; Vávra P; Zonča P
World J Gastroenterol; 2015 Jun; 21(22):7014-21. PubMed ID: 26078580
[TBL] [Abstract][Full Text] [Related]
16. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
Maithel SK; Gönen M; Ito H; Dematteo RP; Allen PJ; Fong Y; Blumgart LH; Jarnagin WR; D'Angelica MI
Surgery; 2012 Feb; 151(2):162-70. PubMed ID: 21982065
[TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary approach of colorectal liver metastases.
Juez I; Rubio C; Figueras J
Clin Transl Oncol; 2011 Oct; 13(10):721-7. PubMed ID: 21975333
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive markers in liver limited stage IV colorectal cancer.
Rehman AH; Jones RP; Poston G
Eur J Surg Oncol; 2019 Dec; 45(12):2251-2256. PubMed ID: 31279594
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Adjuvant Chemotherapy According to the Classification of Recurrence Risk Based on Systemic Inflammatory Markers in Patients With Liver Metastases of Colorectal Cancer.
Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
Anticancer Res; 2019 Sep; 39(9):5039-5045. PubMed ID: 31519612
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker.
Køstner AH; Kersten C; Löwenmark T; Ydsten KA; Peltonen R; Isoniemi H; Haglund C; Gunnarsson U; Isaksson B
J Surg Oncol; 2016 Dec; 114(7):895-899. PubMed ID: 27696432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
